DBVT | tickerfilter.com

Fundamental analysis

34%

Profitability 35%

Dept financing 31%

Liquidity 49%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-6.48%

1 Month

-2.72%

3 Months

-19.97%

6 Months

32.17%

1 Year

112.10%

2 Year

2,788.24%

Key data

Stock price

$19.64

P/E Ratio

N/A

DAY RANGE

$19.27 - $20.12

EPS

-$1.13

52 WEEK RANGE

$7.53 - $26.18

52 WEEK CHANGE

$120.67

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

296.042 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

-0.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$273,202

AVERAGE 30 VOLUME

$258,905

Company detail

CEO: Daniel Tassé
Region: US
Website: dbv-technologies.com
Employees: 80
IPO year: 2014

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

DBV Technologies S.A. engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus.

DBVT - DBV Technologies S.A.